Want to see IN:NGLFINE full AI Analyst Report?
NGLFINE Stock Chart & Stats
₹3194.85
₹21.00(0.66%)
At close: 4:00 PM EDT
₹3194.85
₹21.00(0.66%)
Day’s Range― - ―
52-Week Range₹1,261.00 - ₹3,595.00
Previous CloseN/A
Volume7.53K
Average Volume (3M)583.00
Market Cap
₹16.34B
Enterprise Value₹13.58B
Total Cash (Recent Filing)₹442.99M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)28.6
Beta1.07
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.07%
Share Statistics
EPS (TTM)92.59
Shares Outstanding6,178,024
10 Day Avg. Volume199
30 Day Avg. Volume583
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)3.86
Price to Sales (P/S)2.54
P/FCF Ratio-25.26
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Re-accelerationThe return to 22.6% revenue growth after a nearly flat year indicates improving demand for the company’s APIs, intermediates, and specialty chemicals. Sustained top-line expansion can support better capacity utilization, broaden customer engagement, and provide a foundation for continued earnings growth over the coming quarters.
Profitability RecoveryThe improvement in net margin and operating margin shows that stronger revenue translated into better reported profitability in 2026. Although margins remain below prior peaks, this recovery strengthens internal funding capacity and suggests operating performance has begun to improve alongside renewed demand.
Manageable Balance-Sheet LeverageDebt-to-equity remains at a moderate level, while steady equity and asset growth provide balance-sheet capacity for ongoing operations and investment. This financial position gives the company more resilience than a highly leveraged model and leaves room to support growth despite debt increasing.
Bears Say
Weak Cash ConversionLow conversion of accounting profit into operating cash reduces the quality and flexibility of earnings. Persistent negative free cash flow also indicates that reinvestment and/or working-capital demands are absorbing cash, which can constrain self-funded expansion and increase reliance on balance-sheet resources.
Gross-Margin CompressionThe sharp decline in gross margin signals weaker economics at the product or input-cost level, even though net profitability recovered. If the lower gross-margin structure persists, it could limit operating leverage, reduce the benefit of revenue growth, and make future earnings more sensitive to mix and cost conditions.
Rising Leverage And Incomplete Returns RecoveryThe increase in debt relative to equity raises the company’s financial obligations while returns on equity remain below their stronger historical range. This combination suggests that recent growth has not yet restored peak profitability and may leave less flexibility if earnings or cash generation weaken.
NGL Fine-Chem Ltd. News
NGLFINE FAQ
What was NGL Fine-Chem Ltd.’s price range in the past 12 months?
NGL Fine-Chem Ltd. lowest stock price was ₹1261.00 and its highest was ₹3595.00 in the past 12 months.
What is NGL Fine-Chem Ltd.’s market cap?
NGL Fine-Chem Ltd.’s market cap is ₹16.34B.
When is NGL Fine-Chem Ltd.’s upcoming earnings report date?
NGL Fine-Chem Ltd.’s upcoming earnings report date is Nov 06, 2026 which is in 11 days.
How were NGL Fine-Chem Ltd.’s earnings last quarter?
NGL Fine-Chem Ltd. released its earnings results on Aug 12, 2026. The company reported ₹29.778 earnings per share for the quarter.
Is NGL Fine-Chem Ltd. overvalued?
According to Wall Street analysts NGL Fine-Chem Ltd.’s price is currently Overvalued.
Does NGL Fine-Chem Ltd. pay dividends?
NGL Fine-Chem Ltd. pays a Annually dividend of ₹1.75 which represents an annual dividend yield of 0.07%. See more information on NGL Fine-Chem Ltd. dividends here
What is NGL Fine-Chem Ltd.’s EPS estimate?
NGL Fine-Chem Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NGL Fine-Chem Ltd. have?
NGL Fine-Chem Ltd. has 6,178,024 shares outstanding.
What happened to NGL Fine-Chem Ltd.’s price movement after its last earnings report?
NGL Fine-Chem Ltd. reported an EPS of ₹29.778 in its last earnings report. Following the earnings report the stock price went down -1.376%.
Which hedge fund is a major shareholder of NGL Fine-Chem Ltd.?
Currently, no hedge funds are holding shares in IN:NGLFINE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NGL Fine-Chem Ltd.
Headquartered in Mumbai, India, and established in 1981, NGL Fine-Chem Limited operates as a worldwide producer and distributor of pharmaceutical ingredients and intermediates for both veterinary and human health sectors. The company's comprehensive portfolio of active pharmaceutical ingredients (APIs) for animal applications features substances like diminazene aceturate, diminazene diaceturate, homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosphan, imidocarb dipropionate, triclabendazole, ractopamine HCl, S-methoprene, praziquantel, toltrazuril, decoquinate, flunixin meglumine, carprofen, fenbendazole, amitraz, and marbofloxacin. For human therapeutic use, they supply APIs including nitazoxanide, atovaquone, and ranolazine. Furthermore, NGL Fine-Chem manufactures various intermediate compounds and offers completed pharmaceutical formulations in both granule and tablet formats.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
SMS Pharmaceuticals Limited
―
Senores Pharmaceuticals Ltd.
―